New Actos Lawsuits Alleging Bladder Cancer Filed; Resource4thePeople Attorneys Continue to Review Cases as Litigation Advances
The number of lawsuits in a Louisiana multidistrict litigation has climbed to more than 1,300 cases over claims that use of diabetes drug can allegedly lead to bladder cancer. Free consultations still available to consumers.
San Diego, CA (PRWEB) June 19, 2013
Resource4thePeople announced today its latest update for consumers who are following the litigation involving claims that use of the diabetes drug allegedly can cause patients to develop bladder cancer.
New lawsuits are being filed are being across the country as the number of cases in a multidistrict federal court litigation overseen by a U.S. District judge in Louisiana has climbed to over 1,300, according to the court files in the litigation.*
The court docket also shows that Judge Rebecca F. Doherty has scheduled a June 20, 2013 status conference in the litigation in which lawyers for the hundreds of plaintiffs and those for Actos will inform her about important developments in evidence-gathering and other legal matters in the consolidated lawsuits.
“Resource4thePeople is encouraged that this important litigation is continuing to progress through our court system,” said spokesman William Howell. “We await the next developments in the litigation and will continue to provide them in our consumer updates.
“We also note that additional lawsuits alleging that the use of Actos caused bladder cancer have been filed across the country and that Resoruce4thePeople is continuing to review inquiries from consumers with free consultations over alleged cases of bladder cancer.”
Two of the most recent Actos lawsuits alleging bladder cancer were filed May 23, 2013 in Louisiana** and June 10, 2013 in New Jersey,*** both against Takeda Pharmaceuticals, the manufacturer of Actos.
In the New Jersey case, an Arizona man claims that he developed cancer after taking Actos (pioglitazone) after using it for five years.
In the New Jersey case, a woman is alleging that her father, Ralph Liscio, died of bladder cancer as a result of his use of Actos to treat his diabetes.
“As a result of the defective nature of Actos, [Liscio], who was prescribed and who ingested this product, suffered and died from bladder cancer and related medical conditions,” according to the allegations in the complaint that was filed. “Defendants concealed and continue to conceal their knowledge of Actos´ unreasonably dangerous risks from [Liscio], his physicians, other consumers and the medical community.”
“The filing of these lawsuits shows that patients and their loved ones are continuing to come forward with similar allegation in which they are alleging that Actos has life-threatening side effects that were not adequately made public to consumers and physicians,” said Resource4thePeople’s Howell.
“We have been receiving numerous inquiries from consumers who are asking how they may be informed about the legal rights they may have in regards to Actos allegations. Because of this we will continue to provide free consultations for these consumers.”
Howell said the volume of inquiries from consumers has increased since the news of a judge’s overturning of a jury’s award of $6.5 million in damages to a California man in the first trial**** in the country over Actos bladder cancer allegations.
The judge in the case ruled that even though the jury in the trial returned a verdict on behalf of the victim, the man’s lawyers didn´t produce sufficient evidence to show his cancer was caused by the medication.*****
Bloomberg News in a May 1, 2013 article, reported that the man’s lawyer said the judge has misinterpreted the law in his decision and promised to appeal the dismissal.
The jury in the Los Angeles Superior Court trial found in favor of Jack Cooper, a 79-year-old man who treated his diabetes with Actos for more than four years before being diagnosed with bladder cancer in 2011, according to testimony presented by his attorneys at the trial.
“As with many trials this case eventually will be decided in the appellate courts and while it is thousands of other cases involving similar allegations will continue to proceed through our courts,” said Resource4thePeople.
Bloomberg News in its report said the case was the first of more than 3,000 pending cases to advance to trial status against Actos and its manufacturer, Takeda Pharmaceuticals.
Cooper´s suit was among state court cases gathered before Judge Kenneth Freeman in Los Angeles. Most other cases are in the multidistrict litigation in Louisiana where Judge Rebecca Doherty has scheduled the first bellwether trial in that litigation to be held in November. Bellwether trials are scheduled to allow attorneys for the plaintiffs and defendants to test the strength of their cases.
Concerns about Actos were raised by the U.S. Food and Drug Administration on June 15, 2011 after the agency staff reviewed a Takeda-sponsored study which documented an increased risk of developing bladder cancer with Actos than other diabetes drugs.******
Here is part of the safety announcement:
“The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.”
“Consumers and diabetes patients should also be aware of the fact that in this health warning the FDA noted that Actos has been pulled from the pharmacy shelves in France and Germany but has not been recalled in the United States,” said Resource4thePeople.
- In Re: Actos (Pioglitazone) Products Liability Litigation, MDL2299 U.S. District Court, Western District of Louisiana
**Case # 6:13cv1235, U.S. District Court for the Western District of Louisiana
***Case # 2:13cv3602, U.S. District Court for the District of New Jersey
****Cooper v. Takeda Pharmaceuticals America, Inc., CGC-12-518535, California Superior Court (Los Angeles)
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/6/prweb10843157.htm